Quality Research On Pharmaceutical Corporate Social Responsibility Information Disclosure

With the development of global social responsibility movement, the countries of the world have strengthened the importance of CSR (Corporate Social Responsibility). The pharmaceutical industry is directly related to medication safety and life health of the people, especially in recent years, since a variety of food and drug safety incidents, false advertising events, labor safety incidents and environmental protection issues occurred, the public business transparency and full disclosure of information required to further improve. Similarly, enterprises have also recognized the necessity to strengthen communication with the public through a comprehensive way, and rebuild investors and other stakeholders’trust in business. Therefore, the listed pharmaceutical enterprises choose to disclose social responsibility information to the public, hoping to establish and enhance their credibility, improve the brand recognition. However, because of the lack of disclose specification, the quality of the pharmaceutical CSR information disclosure is uneven now. By improving the quality of CSR information disclosure, the pharmaceutical enterprises are able to attract more market attention. But there has no effective evaluation. At present, although there are many literatures on social responsibility information disclosure, but targeted research on pharmaceutical enterprises are not enough. Through building up a pharmaceutical CSR information disclosure evaluation system, and taking KM Pharmaceutical Company as an example, this research tried to provide a reference for corporate self-review and improvement of social responsibility information disclosure.This paper firstly theoretically analyzed the importance of social responsibility information disclosure, then compared the present situation among pharmaceutical enterprises and found that the disclosure quality varied greatly. In this case, it is necessary to put forward suitable evaluation standards for social responsibility. Enterprises could find the problems existing among the practice and information disclosure of social responsibility according to the evaluation standards and improve the information disclosure quality. Secondly, based on the characteristics of disclosure of social responsibility, this paper established an evaluation system which contains general indicators as well as indicators reflecting industry characteristics and carried out validation test over that evaluation system. Third, this paper applied the evaluation system to KM pharmaceutical enterprises social responsibility information disclosure, and found that the quality of information level of KM was below the medium level among its trade. On the basis of the above evaluation system, this paper deeply analyzed the problems of the information disclosure of KM, and put forward to suggestions of improving the information disclosure quality and strengthening the management over social responsibility in pharmaceutical enterprises.Through systematic study, this paper found that a small number of pharmaceutical enterprises developed their own strategies for social responsibility and gained the initial invisible earnings in the process of managing social responsibility and effectively disclosing information of social responsibility. However, most enterprises had a lower understanding of social responsibility and were reluctant to disclose relevant information. In this way, the quality of social responsibility information disclosure were in severe imbalance and largely dependent on the policy oversight of the regulatory authorities. In terms of improving the quality of CSR disclosure, China’s pharmaceutical enterprises still have a long way to go.